Abbott Laboratories Corporation

Biomarin Pharmaceutical Inc.

Kosan Biosciences Incorporated

Medivation Technologies, Inc.

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Other

Novartis Ag

Daniel T Chu

Bing Wang

Yat Sun Or

Jacob J Plattner

Zhenkun Ma

Richard F Clark

George W Griesgraber

Qun Li

Curt S Cooper

Rustum S Boyce

Chaitan Khosla

Daniel V Santi

Christopher Reeves

Terry J Rosen

Anthony K Fung

Robert Hallas

Wei-Bo Wang

Bryan H Chang

Aaron Matthew Smith

David Duhl

Natalia Aurrecoechea

Kai Wu

Yongbo Liu

Gary W Ashley

Matthew T Burger

Cheuk M Lee

Richard L Elliott

Ying Feng

Yuqiao Shen

Leonard Edwin Post

Paul A Renhowe

Ly Tam Phan

Alexander James Bridges

Andreas W Schirmer

Lisa A Hasvold

Larry L Klein

Maria Fardis

Xiaodong Lin

Zhi-Jie Ni

Lester A Mitscher

Daisy Pireh

Leping Li

Jason Kang

Shichun Peng

Quan Jiang

Lei Lu

Georgia Law Carroll

Jerry R Martin

Kirk William Johnson

Yan Chen

Ming Clinton Yeung

David C Myles

Michael D Tufano

Stephen Andrew Thomson

David J Grampovnik

Sheela A Thomas

David Lee Musso

Paul A Lartey

Alice C Rico

Jason Daniel Speake

Michael Joseph Bishop

Francis A Kerdesky

Andre G Pernet

Alford M Thomas

David A Degoey

Chi-nung W Hsiao

Christina Louise Leone

Kenneth P Spina

Christopher R Conlee

Kien S Du

Brian D Thompson

Linus L Shen

Alice Rico

Jacob J Platter

Kathleen Raye

Maria N Preobrazhenskaya

Delia Aguilar

Svetlana S Printsevskaya

Eugenia N Olsufyeva

Judith De Armas Kuntz

Kevin K Barvian

William R Swain

Brian A Chauder

Yaohui Lei

Yu Bai

John Jian-Xin Wang

Effie Tozzo

Aaron Smith

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R, R, R, Rand Rare as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Glucosylceramide synthase inhibitors for the treatment of diseases

The embodiments disclose a method including creating a blunt rolling device for rolling blunt smoking products, rolling a wrapper on a wrapper roller tube to create a blunt wrapper tube with a glass tip, tamping smoking material into the blunt wrapper tube at a user defined density, twisting, cutting and tucking wrapper excess into the glass tip, and controlling the operations of the blunt rolling device using a computer, wireless communications and a blunt rolling method and device program for sequencing processes, operating solenoid drive motors and humidity and temperature devices of a smoking material humidor, adjusting settings of devices using predetermined data stored in digital memory devices and accessed using digital processors.

Blunt rolling method and devices

The embodiments disclose an apparatus including a smoking material care kit, a matchstick and pick combination device for igniting smoking materials, a two-way humidity control pack device for controlling humidity of a smoking material stored in a smoking material protective container, and a protective container safety cap device coupled to the protective container to prevent access to smoking materials inside the protective container by children.

Two way humidity control pack

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R, R, R, Rand Rare as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.

Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt

Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.

Processes of synthesizing dihydropyridophthalazinone derivatives

[object Object]

Growing community of inventors

Santa Clara, CA, United States of America

Daniel T Chu